Amgen (AMGN)
(Delayed Data from NSDQ)
$333.14 USD
+2.99 (0.91%)
Updated Jul 16, 2024 04:00 PM ET
After-Market: $333.14 0.00 (0.00%) 7:58 PM ET
3-Hold of 5 3
C Value D Growth A Momentum C VGM
Brokerage Reports
Amgen Inc. [AMGN]
Reports for Purchase
Showing records 401 - 420 ( 431 total )
Company: Amgen Inc.
Industry: Medical - Biomedical and Genetics
1Q12 results beat expectations despite ESA franchise declines; SELL
Provider: LAZARD
Company: Amgen Inc.
Industry: Medical - Biomedical and Genetics
Company: Amgen Inc.
Industry: Medical - Biomedical and Genetics
Company: Amgen Inc.
Industry: Medical - Biomedical and Genetics
Company: Amgen Inc.
Industry: Medical - Biomedical and Genetics
Company: Amgen Inc.
Industry: Medical - Biomedical and Genetics
ODAC panel not swayed by Xgeva BMFS data - vote 12-1 against approving indication; SELL
Provider: LAZARD
Company: Amgen Inc.
Industry: Medical - Biomedical and Genetics
Company: Amgen Inc.
Industry: Medical - Biomedical and Genetics
Company: Amgen Inc.
Industry: Medical - Biomedical and Genetics
Company: Amgen Inc.
Industry: Medical - Biomedical and Genetics
Company: Amgen Inc.
Industry: Medical - Biomedical and Genetics
Company: Amgen Inc.
Industry: Medical - Biomedical and Genetics
Company: Amgen Inc.
Industry: Medical - Biomedical and Genetics
Company: Amgen Inc.
Industry: Medical - Biomedical and Genetics
Xgeva/Prolio likely to become key growth driver ahead & expected to drive high single digit earnings growth...
Provider: FIRST GLOBAL
Analyst: THOMAS K
Company: Amgen Inc.
Industry: Medical - Biomedical and Genetics
Company: Amgen Inc.
Industry: Medical - Biomedical and Genetics
Company: Amgen Inc.
Industry: Medical - Biomedical and Genetics
Xgeva/Prolio likely to be a key driver & help record high single-digit earnings growth...
Provider: FIRST GLOBAL
Analyst: THOMAS K
Company: Amgen Inc.
Industry: Medical - Biomedical and Genetics
Company: Amgen Inc.
Industry: Medical - Biomedical and Genetics
Company: Amgen Inc.
Industry: Medical - Biomedical and Genetics
Modest topline growth & high single digit EPS growth expected over next five years, driven by approval of Prolia (denosumab) in cancer & Part D reimbursement coming online in early CY11....
Provider: FIRST GLOBAL
Analyst: THOMAS K